Kornimate/medical-research-clean huggingface dataset:
safety and effectiveness of cpi-1189 in hiv-infected males on combination anti-hiv drug therapy

Conditions: AIDS Dementia Complex; HIV Infections

Summary: the purpose of this study is to see if it is safe to give multiple doses of cpi-1189 to hiv-infected, otherwise healthy, males. the study will also look at how cpi-1189 affects the levels of hiv, t cells (cells in the body that help fight infection), and three anti-hiv drugs (zidovudine, lamivudine, and indinavir) in the blood. advanced hiv infection can cause aids dementia (brain damage due to hiv leading to losses of memory and muscle control). cpi-1189 may be able to postpone aids dementia or slow it down.

late-stage hiv infection can cause aids dementia (brain damage due to hiv leading to losses of memory and muscle control). cpi-1189 may be able to postpone aids dementia or slow it down. in this randomized, double-blind study, 48 hiv-infected, otherwise healthy, male volunteers receive either multiple-dose cpi-1189 or placebo by mouth for 15 consecutive days. each dosing group begins 6 weeks following the start of the preceding group. volunteers enter the study site the night before dosing on days 1 and 15 and remain at the study site for 72 hours following dosing. throughout the study, volunteers have physical exams and donate samples of blood, urine, cerebrospinal fluid, and sperm.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are an hiv-positive man who is otherwise in good health. * are 18-50 years old. * have a cd4 count of 75-500 cells/mm3. * are currently taking zidovudine (zdv), lamivudine (3tc), and indinavir (idv).

Keywords: dose-response relationship, drug drug therapy, combination aids dementia complex zidovudine lamivudine indinavir reverse transcriptase inhibitors
two handed jaw-thrust on postoperative sore throat after double-lumen endotracheal tube insertion

Conditions: Lung Surgery

Summary: this investigation is planned to compare the incidence and severity of postoperative sore throat according to the use of two-handed jaw thrust maneuver in patients undergoing double-lumen endotracheal intubation.


Eligibility criteria:
inclusion criteria: * asa i-iii * patients scheduled for double-lumen endotracheal intubation exclusion criteria: * difficult airway * mallampatti scores greater than 3 * recent sore throat * cervical spine disease * history of head and neck surgery

Keywords: intubation pharyngitis
suprascapular cuff study: assessing the effects of size and type of rotator cuff tear on suprascapular nerve function

Conditions: Orthopedic Disorder

Summary: the primary objective of the study is to determine in adult patients with a rotator cuff tear, what size and pattern of rotator cuff tear would result in damage to the suprascapular nerve. the secondary objectives are 1. to determine if an injured suprascapular nerve can recover if the rotator cuff tear is surgically repaired. 2. to determine if there is a limit of retraction before the suprascapular nerve is irreversibly damaged. 3. to determine factors that are protective against ssn injury. 4. can the patient data gathered be used to optimise operative procedures.


Eligibility criteria:
inclusion criteria: • all patients age ≥18 years presenting to a uhnm shoulder clinic with a confirmed diagnosis of a rotator cuff tear (affecting one or both shoulders). exclusion criteria: * bony pathology (such as significant shoulder arthritis that would exclude isolated rotator cuff repair) * grossly abnormal shoulder anatomy * motor neurone disease * cervical cord disease affecting the ssn nerve roots * patients unable to undergo mri scan * previous surgery at the affected glenohumeral joint * patients unable to tolerate ncs * acute fracture affecting the glenohumeral joint * recent glenohumeral joint dislocation (past 12 months) * patients unable or unwilling to give full informed consent * patients unable or unwilling to comply with the study procedures

Keywords: rotator cuff tear suprascapular nerve function
cognitive impairment in older hiv-infected patients ≥ 65 years old

Conditions: Memory Impairment; HIV/AIDS; Cognitive Impairment

Summary: despite combined antiretroviral therapy (cart), milder forms of hiv-associated neurocognitive disorders (hand) persist in 20-50% of persons living with hiv (plhiv). since more plh are at risk for hand due to aging, the frequency of hand in plhiv ≥ 65 years old is important to quantify for planning early intervention to attenuate both functional and occupational disabilities due to cognitive impairment.


Eligibility criteria:
inclusion criteria: * personal or familial cognitive complaints * individual aged ≥ 65 years old and \< 81 years old * instrumental activities of daily living (iadl) score between 3-4 * french speaking individual * informed consent signed for plhiv * hiv infection * undetectable hiv viral load ≥ 1 year * current cluster of differentiation (cd4) cell count \> 100/mm3 for controls * negative hiv serology ≤ 6 months exclusion criteria: * opportunistic infection \< 5 years * contraindications to mri
serum alkaline phosphatase levels in healthy turkish children

Conditions: Alkaline Phosphatase Deficiency; Vitamin D Deficiency

Summary: alkaline phosphatase (alp), is a metalloenzyme of the plasma membrane. serum alp levels in children are closely related to age and gender, many commercial test kits being used in hospitals, are only offering reference values for adults. the aim of this study is to determine serum alp levels regarding to age, gender and pubertal stage.

alkaline phosphatase (alp), is a metalloenzyme of the plasma membrane. serum alp levels in children are closely related to age and gender, many commercial test kits being used in hospitals, are only offering reference values for adults. the aim of this study is to determine serum alp levels regarding to age, gender and pubertal stage methods: this stuy has been proceeded on children, who have no history for a chronic diseasse or medication and attending to the keçiören education and research hospital pediatric policlinic for routine control between september 2012-september 2013. in order to determine the serum alkaline phosphatase levels in children, 1063 (511 male, 552 female) patients were incorporated. ca, p and vitamin d levels were also evaluated. the ranges of serum alp levels in both genders according to age has been determined.

Eligibility criteria:
inclusion criteria: * healthy * without chronic diseases exclusion criteria: * with chronic diseases

Keywords: alkaline phosphatase vitamin d deficiency
changes in ciliary body thickness in patients with diabetic macular edema after vitrectomy

Conditions: Diabetic Macular Edema

Summary: the purpose of this study is to determine whether ciliary body thickness increased in the presence of diabetic macular edema and whether it changed after pars plana vitrectomy.

a diabetic macular edema group consisted of diabetic patients who underwent ppv for diffuse diabetic macular edema. a epiretinal membrane group, a surgical control group, consisted of non-diabetic patients with epiretinal membrane who underwent pars plana vitrectomy. a healthy control was also included for the comparison of preoperative ciliary body thickness. ciliary body thickness was measured using ultrasound biomicroscopy, and central macular thickness was determined using optical coherence tomography. the visual outcome, ciliary body thickness, and central macular thickness were compared between groups before and 1, 2, and 4 months after pars plana vitrectomy and the correlations between the central macular thickness and ciliary body thickness and best corrected visual acuity were determined.

Eligibility criteria:
inclusion criteria for diabetic macular edema group: * diabetic macular edema with preoperative central macular thickness \> 300 μm on optical coherence tomography * macular edema that was not associated with an epiretinal membrane or traction membrane * no combined traction retinal detachment or vitreous hemorrhage * no signs of ocular inflammatory disease on preoperative examination * phakic eye * an axial length between 22.0 mm and 25.0 mm exclusion criteria for diabetic macular edema group: * patients with uveitis, inflammatory connective tissue disorders or a history of previous ocular surgery * long-term application of topical medication, a history of intravitreal steroid or anti-vegf injection within 3 months before vitrectomy inclusion criteria for epiretinal membrane group: * non-diabetic patients with an epiretinal membrane who were scheduled for vitrectomy * no ocular or systemic disease other than epiretinal membrane inclusion criteria for healthy group: * no diabetes * no ocular disease other than cataract

Keywords: diabetic macular edema ciliary body ultrasound biomicroscopy vitrectomy
evaluation of an karajishi contour investigational blood glucose monitoring system (iso/fda study)

Conditions: Diabetes

Summary: the purpose of this study was to determine if untrained persons with diabetes and without diabetes could operate the investigational blood glucose monitoring system (bgms) and obtain valid blood glucose results.


Eligibility criteria:
inclusion criteria: * males and females, 18 years of age and older * able to speak, read, and understand english * willing to complete all study procedures exclusion criteria: * hemophilia or any other bleeding disorder * pregnancy * physical, visual, or neurological impairments that would make the person unable to perform testing with the bgm * previously participated in a bg monitor study using the karajishi contour bgms (or used a bayer contour meter) * work for a medical laboratory, hospital, or other clinical setting that involves training on and clinical use of blood glucose monitors * work for a competitive medical device company, or having an immediate family member who works for such a company * a condition which, in the opinion of the investigator or designee, would put the person or study conduct at risk general enrollment guidelines: * most subjects will be persons with type 1 or type 2 diabetes * at least 10% of subjects with diabetes will have type 1 diabetes * approximately 10% of subjects will be persons without diabetes * at least 60% of subjects will be younger than age 65
assessment of progesterone receptors in breast carcinoma by positron emission tomography (pet) using fluoro furanyl norprogesterone (ffnp)

Conditions: Breast Cancer

Summary: the purpose of this study is to see if positron emission tomography (pet) imaging with a radioactive form of the hormone progesterone called ffnp will give the same results as hormone receptor testing already performed on tissue used to diagnose breast cancer.


Eligibility criteria:
inclusion criteria: * female patients 18 years of age or older * biopsy-proven breast cancer * tumor estrogen-receptor and progesterone-receptor status already determined or scheduled to be determined at time of surgery without intervening therapy. * primary lesion size ≥ 1.5 cm as determined by imaging studies (ultrasonography, mammography, ct or mri) or physical examination * able to give informed consent * not currently pregnant or nursing: subject must be surgically sterile (has had a documented bilateral oophorectomy and / or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), non lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of ffnp) is negative. exclusion criteria: * no previous history of hormone therapy; note - subjects who were treated with hormone therapy for reasons other than breast cancer or breast cancer prevention may be allowed to participate after review of history by the primary investigator * patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years * unable to tolerate 60-90 minutes of pet imaging per imaging session

Keywords: breast cancer hormone receptor
acyclovir in preventing herpes simplex virus infection in patients with neutropenia

Conditions: Herpes Simplex

Summary: rationale: acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. purpose: this randomized phase iii trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.

objectives: * to determine the difference in nephrotoxicity between low-dose and weight-based intravenous acyclovir sodium as herpes simplex virus infection prophylaxis in patients with neutropenia. outline: patients are randomized to 1 of 2 treatment arms. * arm i: patients receive weight-based iv acyclovir sodium every 8 or 12 hours. * arm ii: patients receive low-dose iv acyclovir sodium every 8 or 12 hours. treatment continues for approximately 2 weeks unless clinical herpes simplex virus infection is confirmed or the patient is no longer neutropenic.

Eligibility criteria:
inclusion criteria: * be 18 years of age or older. * receiving treatment in inpatient oncology services at wake forest university baptist medical center * receiving chemotherapy or have received chemotherapy within the past 2 weeks * seropositive herpes simplex virus (hsv)-1 or hsv-2 immunoglobulin antibody assay * creatinine clearance ≥ 50 ml/min * intravenous acyclovir sodium therapy is deemed necessary by the physician based upon clinical judgement (i.e., mucositis, vomiting, decreased gi absorption) exclusion criteria: * pregnant or nursing * hypersensitivity to acyclovir sodium * high tumor burden (i.e., wbc \> 50,000/mm\^3 at admission) * neutropenic, defined as one of the following: * anc \< 500/mm\^3 * anc \< 1,000/mm\^3 with a predicted decrease to 500/mm\^3 * active hsv infection, as evidenced by any of the following: * positive hsv cultures * oral lesions * receiving 5 mg/kg acyclovir sodium every 8 hours

Keywords: chemotherapeutic agent toxicity renal toxicity infection neutropenia
role of bcl-b in multiple myeloma

Conditions: Multiple Myeloma

Summary: mm accounts for 10% of hematopoietic malignancies. despite the use of various drug combinations in chemotherapy, life expectancy of mm patients does not exceed 7 years. until now, lack of specific markers of the disease has not allowed efficient specific molecular targeting. in view of our preliminary results, the antiapoptotic protein bcl-b could be a novel diagnostic and pronostic marker of mm. therefore, our main objective will be to confirm that bcl-b is indeed a novel diagnostic and pronostic marker and a new potential therapeutic target of mm. targeting bcl-2 family member's is a promising strategy for the treatment of hematopoietic malignancies. in this context, specific targeting of bcl-b could improve the treatment of patients suffering mm. of note, this could be achieved by converting the antiapoptotic function of bcl-b to a proapoptotic one thanks to the use of small mimetic peptides derived from nur77 one of its interactors.


Eligibility criteria:
patients with multiple myeloma and mgus newly diagnosed at the service de medecine interne-cancerologie department of the nice chu
use of ozonized water with toothpaste and mousse in non surgical periodontal therapy for patients with diabetes mellitus type 1: a randomized clinical trial.

Conditions: Diabetes Mellitus With Periodontal Disease

Summary: the aim of this study is to evaluate the efficacy of peribioma toothpaste and mousse for home oral care in patients with diabetes mellitus type 1. patients will undergo a professional oral hygiene procedure, followed by irrigation with ozonized water. patients will be randomly divided into two groups: * trial group: patients will use biorepair peribioma toothpaste and mousse for home oral care * control group: patients will use biorepair plus parodontgel toothpaste for home oral care. the variations of the following indices will be evaluated at the baseline, after 3 and 6 months: glycosylated hemoglobin (hba1c) , clinical attachment level (cal), plaque index (pi), probing pocket depth (ppd) and bleeding on probing (bop).

the aim of this study is to evaluate the efficacy of peribioma toothpaste and mousse for home oral care in patients with diabetes mellitus type 1. patients who respond to eligibility criteria and that will sign the informed consent will undergo a professional oral hygiene procedure; then, ozonized water (aquolab) will be used to irrigate periodontal pockets for 1 minute. then, patients will be randomly divided into two groups: * trial group: patients will use biorepair peribioma toothpaste and mousse for home oral care until the end of the study; * control group: patients will use biorepair plus parodontgel toothpaste for home oral care until the end of the study. changes in the following indices will be evaluated at the baseline, after 3 and 6 months: glycosylated hemoglobin (hba1c) , clinical attachment level (cal), plaque index (pi), probing pocket depth (ppd) and bleeding on probing (bop).

Eligibility criteria:
inclusion criteria: * patients suffering from diabetes mellitus type 1 * adult patients * patients who agreed to participate to the study and that signed the informed consent. exclusion criteria: * patients taking intravenous or oral bisphosphonates at the study begin or in the previous 12 months * patients with low compliance and motivation to participate * pazienti irradiati alla testa o collo negli ultimi 12 mesi * pregnant or breastfeeding women * alcohol and drug abuse * patients with psychiatric diseases

Keywords: ozonized water glycosylated hemoglobin
pain evaluation of venous cannulation to predict postoperative pain

Conditions: Pain, Postoperative

Summary: the investigators have recently reported a relationship between pain induced by peripheral venous cannulation and postoperative pain. the purpose of this study is to validate this method of postoperative pain prediction in a larger cohort subjected to different types of surgery.

* the investigators will study all adult (\>18 years old) patients going through surgery at the site during a defined period of time. before induction of anesthesia participants will be asked to assess (in vas units) the pain intensity associated with peripheral venous cannulation. the maximum level of postoperative pain intensity will be recorded in the post-anesthesia care unit. * after the endpoint of the study, the patient records will be reviewed, and de-identified relevant data be recorded and analyzed in the statistical package for the social sciences (spss) software. * sample size assessment: in a previous study patients scoring ≥ 2.0 on venous cannulation assessed their median pain postoperatively at 5.8 vas units compared with 2.9 in those scoring \< 2.0 - corresponding to a difference in maximum postoperative pain intensity of almost three vas units. to statistically confirm, with unpaired non-parametric tests, 80 % power (β), and 95% probability (1- α), half of that difference (1.5 vas units) in pain intensity level between patients scoring above or below 2.0 vas units, respectively, would require 55 patients in each group subjected to the same kind of surgery. with 4 groups of cases and controls 440 patients would need to be included. as the study is strictly observational, 600 patients will be included to make up for possible missing data. * statistics: the mann-whitney u- test will be used to compare differences in postoperative pain intensity levels, and the pearson chi-square test to compare proportions of patients with moderate or severe postoperative pain, in patients differing in pain scores (above or below 2.0 vas units) on venous cannulation. logistic regression analysis will be used to adjust for gender and age and to evaluate the predictive ability of proposed method.

Eligibility criteria:
inclusion criteria: * 18-80 years old * scheduled for surgery in halmstad * prepared for surgery in the preoperative ward or ward 71 (day-case or direct admittance) exclusion criteria: * inability to handle the visual analog scale * hospitalized already before surgery
the moli-sani study

Conditions: Cardiovascular Diseases; Cardiovascular Risk Factor; Cancer; Neurodegenerative Diseases; Diabetes; Pulmonary Disease

Summary: cardiovascular disease and malignancies account for more than 70% of all causes of mortality and morbidity in italy. there is a subtle balance between genetic determinants and lifestyle, that often defines the line between health and sickness. so far studies aiming at identifying risk factors have mainly come from northern europe and the usa. it was to understand this balance between genetics and environmental determinants better, and to tailor appropriate preventive strategies for italian and other southern european populations, that the moli-sani study was launched, transforming a small italian region into a large scientific laboratory: the "molise lab". each participant received a thorough medical check-up at no cost to either him/her or the national health service, resulting in thousands of hours of free public health care. with a completely computerized system, moli-sani is a "paperless" study, in which researchers and participants communicate using recently developed technologies such as mobile phone text messages (sms). the biological data bank (the "molibank") is one of the largest in europe. paying particular attention towards innovation and new technologies, the moli-sani study has placed itself at the cutting edge of a new paradigm crossing research and prevention

the cohort of the moli-sani study has recruited 24,325 persons, aged \>35 years, resident in the molise region.the latter covers an area of 4,438 km2, including 136 towns. participants are recruited from city-hall registries by a multistage sampling. firstly townships were sampled in three major areas of molise region, starting from the main cities (campobasso, termoli, isernia) by cluster sampling, then, within each township, participants are selected by simple random sampling, using electronically generated numbers.exclusion criteria are pregnancy at the time of recruitment, disturbances in understanding or willingness, current poly-traumas or coma, refusal to sign the informed consent form. all subjects identified are sent a letter inviting them to participate in the project, followed a few days later by a phone call. the recruitment started in the area of campobasso, then it moved to the areas of termoli.

Eligibility criteria:
inclusion criteria: * resident in the molise region (italy), aged \>35. exclusion criteria: * pregnancy at the time of recruitment, disturbances in understanding or willingness, current poly-traumas or coma, refusal to sign the informed consent form.